公开(公告)号：EP2132299A2

公开(公告)日：2009-12-16

申请号：EP08726385.1

申请日：2008-03-03

申请人： Cryo-Cell International, Inc. ,  Walton, Mercedes A. ,  Allickson, Julie G.

发明人： WALTON, Mercedes, A. ,  ALLICKSON, Julie, G.

IPC分类号： C12N5/00

CPC分类号： G01N33/5073 ,  A01N1/02 ,  A01N1/0221 ,  A61K8/983 ,  A61K35/14 ,  A61K35/48 ,  A61K2800/10 ,  A61Q5/00 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/08 ,  C12N5/0682 ,  G01N33/689 ,  G01N2333/705

摘要： Compositions comprising menstrual stem cells (MSCs) and methods, processes, and system therefore are provided by the invention. MSCs are processed from menstrual flow collected during menses. MSCs may be cryopreserved, processed through various culturing and selection steps in preparation for cryopreservation, or processed for therapeutic or cosmeceutical use. Cryopreserved MSCs may be thawed in preparation for therapeutic and cosmeceutical use. MSCs express CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I, and have low or no expression of CD3 and HLA class II.

公开(公告)号：EP2212418A1

公开(公告)日：2010-08-04

申请号：EP08845236.2

申请日：2008-10-31

申请人： Cryo-Cell International, Inc. ,  Allickson, Julie G.

发明人： ALLICKSON, Julie, G. ,  WALTON, Mercedes, A.

IPC分类号： C12N5/08

CPC分类号： C12N5/0647 ,  C12N2502/137 ,  C12N2502/1388 ,  C12N2502/243

摘要： Methods are provided for obtaining expanded human cord blood cells expressing CD34. The methods involve seeding a sufficient amount of cord blood cells with a sufficient amount of menstrual cells under co-culture conditions suitable to promote expansion of the cord blood cells, and co-culturing the cord blood cells with the menstrual cells under culture conditions that support at least two or more population doublings of the cord blood cells. Methods are also provided for growing expanded human cord blood cells to give rise to any one of colony forming units, colony forming unit granulocyte macrophages (CFU-GM), burst forming unit erythroids (BFU-E), and colony forming unit granulocyte erythrocyte macrophage megakaryocyte (CFU- GEMM) blood lineage precursor cells. The expanded cells may express CD34, SSEA-4, and HLA-II. Compositions of the expanded cells are also provided.

摘要翻译： 提供了用于获得表达CD34的扩增人脐带血细胞的方法。 所述方法包括在足以促进脐带血细胞扩增的共同培养条件下接种足够量的脐带血细胞和足量的月经细胞，并在支持培养条件下共培养脐带血细胞与月经细胞 至少两次或更多次脐带血细胞的群体倍增。 还提供了用于生长扩增的人脐带血细胞以产生集落形成单位，集落形成单位粒细胞巨噬细胞（CFU-GM），爆发形成单位红细胞（BFU-E）和集落形成单位粒细胞红细胞巨噬细胞 巨核细胞（CFU-GEMM）血液谱系前体细胞。 扩增的细胞可以表达CD34，SSEA-4和HLA-II。 还提供了扩展细胞的组成。

公开(公告)号：EP2553089A1

公开(公告)日：2013-02-06

申请号：EP11763511.0

申请日：2011-04-01

申请人： Cryo-Cell International, Inc.

发明人： WALTON, Mercedes, A. ,  ALLICKSON, Julie, G. ,  GARCIA-MORALES, Rolando, O.

IPC分类号： C12N5/071

CPC分类号： A61K35/48 ,  A61K35/14 ,  C12N5/0682

摘要： Therapeutic compositions for improving wound healing and related methods of formulation and use are provided. The therapeutic compositions comprise a dosage of MSCs seeded to any one of a biodegradable matrix, a gel, or a solution suitable for subcutaneous injection. The dosage of MSCs may range from about 1X106 MSCs to about 1X1010 per administration. The administration regime may be daily, weekly, or monthly. The dosage and treatment intervals may be adjusted depending upon a patient's response to treatment. The therapeutic compositions may be co-administered, such as for example, topical application of a seeded matrix or gel combined with simultaneous or other recurring subcutaneous injection of MSCs.

摘要翻译： 提供了用于改善伤口愈合的治疗组合物以及相关的配制和使用方法。 治疗组合物包含接种于生物可降解基质，凝胶或适于皮下注射的溶液中的任一种的一定剂量的MSC。 MSC的剂量范围可以从约1×10 6个MSC到约1×10 10个/次。 管理制度可以是每日，每周或每月。 剂量和治疗间隔可根据患者对治疗的反应进行调整。 治疗组合物可以共同施用，例如局部应用接种的基质或凝胶以及同时或其他经常性皮下注射MSC。

公开(公告)号：EP2200620A1

公开(公告)日：2010-06-30

申请号：EP08830729.3

申请日：2008-09-15

申请人： Cryo-Cell International, Inc.

发明人： WALTON, Mercedes, A. ,  ALLICKSON, Julie, G.

IPC分类号： A61K35/12 ,  C12Q1/02

CPC分类号： G01N33/56983 ,  G01N33/56905 ,  G01N33/56911 ,  G01N33/571 ,  G01N33/6854 ,  G01N2800/26 ,  Y02A50/54

摘要： Methods are provided for obtaining and testing or analyzing a non-venous and non-arterial puncture human fluid or cell sample or human body fluid or cell sample to detect the presence of at least one infectious disease. The sample may be menstrual fluid, endometrial menstrual cells, umbilical cord blood, or amniotic fluid. Confirmatory testing of a corresponding arterial or venous blood sample for comparison to the test results for the non-venous and non-arterial human fluid or cell sample may be performed. The testing may comprise a screening test or a confirmatory test.